10 November 2021

A wrap-up of the Clinical Workshop Melanoma: looking into present approaches and what the future looks like

Bianca-Olivia Nita

Bianca-Olivia Nita

Due to restrictions linked to the pandemic, the Clinical Workshop Melanoma had to be postponed from last year to October this year. The restrictions relaxed and finally being able to come together, the long-expected event could take place. We now look back at a successful workshop that took place on the 5thof October at the Oncode office in Utrecht.

The goal of the event was to bring together clinicians and clinical and basic researchers to discuss the tumor type melanoma, and to discuss current trends and unmet needs both within the clinic and in (clinical) research. The workshop aimed to also explore how basic research can address these unmet clinical needs and to stimulate new collaborations through translational and clinical projects.

Chaired by clinician Karijn Suijkerbuijk (UMCU) and Oncode Investigator Sjoerd van der Burg (LUMC), the topics of the presentations included Familial melanoma, Immune therapy, Tumour and Immune Cell Therapy Combinations, Checkpoint inhibition and the Dutch Melanoma Treatment Registry.

A total of 44 experts - mixing clinical and basic researchers, Oncode researchers, clinicians, and industry - participated in the event. And beyond the interesting presentations, the participants appreciated the setting which opened the space for new and relevant discussions, interaction, and networking.

About 7000 people are diagnosed with melanoma in The Netherlands each year, with 80% of patients being cured by excision and a mortality rate of 900 a year. 10% of the patients have a family history linked to it. Therefore, understanding the genetic basis of melanoma susceptibility gives insight into tumor suppressor mechanisms and provides opportunity for personalized surveillance, prevention and possibly treatment.

At this point, neoadjuvant immunotherapy seems to turn into the number one approach to treating melanoma in the next five years with the ambition of more cure and less surgery. During the event, novel combination therapies were discussed and including the importance of the tumor microenvironment - the event offered a good current overview of the field, comparing current therapies, looking into ongoing clinical trials and what the future can bring.

For future events, please keep an eye on our Event Page.

Other News

Oncode PEP4
(Future) researchers and patients join forces to make true impact
For the second year in a row, Oncode’s Patient Engagement Programme had the opportunity to contribute to the bachelor course ‘Eye for Impact’ for biomedical sciences students at University Medical Center Utrecht (UMCU). A unique example of how to give substance to patient engagement in basic research. Oncode researchers and patient representatives participated in a series of lectures and interactive sessions, where the students experienced first-hand how patients and researchers can partner up.
PeterThijssen
Jos Jonkers Daniel Zingg website
Unravelling genetic mechanism behind tumor formation can improve targeted treatment
New research by the group of Jos Jonkers explains variation in treatment response to FGFR2 inhibitors and provides a way to improve targeted therapy for cancer patients. Their work highlights the importance of analyzing the functional consequences of genetic variants found in tumors.
PeterThijssen
2
Chemotherapy speeds up DNA-level aging
Chemotherapy is an important part of treatment for children with cancer, contributing to the recovery of more and more children. Childhood cancer survivors do sometimes experience late effects from their treatment, including a higher risk of developing a second cancer. That risk is very small, but about five to six times greater than in the ‘normal’ population. In new research, published in Cancer Discovery, the team of Oncode Investigator Ruben Van Boxtel (Princess Máxima Center) shows that accelerated DNA aging turns out to be the main cause of the harmful effect of chemotherapy treatment.
PeterThijssen